Systematic Development of Peptide Inhibitors Targeting the CXCL12/HMGB1 Interaction

of 0.8 ± 0.4 μM). The identification of this peptide represents an important step toward the development of innovative pharmacological tools for the treatment of severe chronic inflammatory conditions characterized by an uncontrolled immune response.